5nmd

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (13:07, 15 November 2023) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 1: Line 1:
==868 TCR Specific for HLA A02 presenting HIV Epitope SLYNTVATL==
==868 TCR Specific for HLA A02 presenting HIV Epitope SLYNTVATL==
-
<StructureSection load='5nmd' size='340' side='right' caption='[[5nmd]], [[Resolution|resolution]] 2.07&Aring;' scene=''>
+
<StructureSection load='5nmd' size='340' side='right'caption='[[5nmd]], [[Resolution|resolution]] 2.07&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[5nmd]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5NMD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5NMD FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[5nmd]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5NMD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5NMD FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.07&#8491;</td></tr>
-
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5nmd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5nmd OCA], [http://pdbe.org/5nmd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5nmd RCSB], [http://www.ebi.ac.uk/pdbsum/5nmd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5nmd ProSAT]</span></td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5nmd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5nmd OCA], [https://pdbe.org/5nmd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5nmd RCSB], [https://www.ebi.ac.uk/pdbsum/5nmd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5nmd ProSAT]</span></td></tr>
</table>
</table>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Serial accumulation of mutations to fixation in the SLYNTVATL (SL9) immunodominant, HIV p17 Gag-derived, HLA A2-restricted cytotoxic T lymphocyte epitope produce the SLFNTIAVL triple mutant "ultimate" escape variant. These mutations in solvent-exposed residues are believed to interfere with TCR recognition, although confirmation has awaited structural verification. Here, we solved a TCR co-complex structure with SL9 and the triple escape mutant to determine the mechanism of immune escape in this eminent system. We show that, in contrast to prevailing hypotheses, the main TCR contact residue is 4N and the dominant mechanism of escape is not via lack of TCR engagement. Instead, mutation of solvent-exposed residues in the peptide destabilise the peptide-HLA and reduce peptide density at the cell surface. These results highlight the extraordinary lengths that HIV employs to evade detection by high-affinity TCRs with a broad peptide-binding footprint and necessitate re-evaluation of this exemplar model of HIV TCR escape.
 +
 +
Dual Molecular Mechanisms Govern Escape at Immunodominant HLA A2-Restricted HIV Epitope.,Cole DK, Fuller A, Dolton G, Zervoudi E, Legut M, Miles K, Blanchfield L, Madura F, Holland CJ, Bulek AM, Bridgeman JS, Miles JJ, Schauenburg AJA, Beck K, Evavold BD, Rizkallah PJ, Sewell AK Front Immunol. 2017 Nov 10;8:1503. doi: 10.3389/fimmu.2017.01503. eCollection, 2017. PMID:29209312<ref>PMID:29209312</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 5nmd" style="background-color:#fffaf0;"></div>
 +
 +
==See Also==
 +
*[[T-cell receptor 3D structures|T-cell receptor 3D structures]]
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Human]]
+
[[Category: Homo sapiens]]
-
[[Category: Cole, D K]]
+
[[Category: Large Structures]]
-
[[Category: Fuller, A]]
+
[[Category: Cole DK]]
-
[[Category: Rizkallah, P J]]
+
[[Category: Fuller A]]
-
[[Category: Sewell, A K]]
+
[[Category: Rizkallah PJ]]
-
[[Category: Cd8+]]
+
[[Category: Sewell AK]]
-
[[Category: Immune system]]
+
-
[[Category: Mhc]]
+
-
[[Category: Tcr]]
+

Current revision

868 TCR Specific for HLA A02 presenting HIV Epitope SLYNTVATL

PDB ID 5nmd

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools